U.S. FDA today authorized Cognoa’s machine learning-based software to help diagnose autism spectrum disorder. The de novo authorization from FDA covers the use of the Cognoa ASD Diagnosis Aid with children 18 months through 5 years of age with potential ASD symptoms. Palo Alto, Calif.–based Cognoa has touted the software as a way to do away […]
Functional connectivity magnetic resonance imaging (fcMRI) may be able to predict the chances of developing autism by the age of 2 in high-risk 6-month old infants, according to a new study in the Science Translational Medicine journal. Autism is characterized by challenges in social skills, repetitive behaviors, speech and nonverbal communication. People with autism also […]
Is 9-month-old Mila Goshgarian at risk for developing autism spectrum disorder (ASD)? Her 4-year-old twin brothers are both on the spectrum, so statistically her chances are at least 20 percent.
By Alal Eran
Alal Eran, PhD, studies the molecular basis of autism at Boston Children’s Hospital and Harvard Medical School.
For the parents of autistic children, few treatment options exist other than powerful anti-psychotic medications or alternative therapies with little supporting clinical evidence. Brian Mullen is hoping to break this pattern with the Vayu Vest, a device that uses a treatment method called "deep pressure touch simulation," one of the most well-established alternative therapies. Mullen hopes that his device will become the first FDA-approved medical device to treat autism.